A b cell depleting agent for the treatment of atherosclerosis or post myocardial infarction

New anti-atherogenic strategies based on B cell modulation, and suggest that patients currently treated with CD20 antibodies for other immune-mediated diseases might also benefit from a reduction of cardiovascular risk through limitation of atherosclerotic lesion development or inflammation. CD20-antibody-mediated depletion of mature B lymphocytes impeded monocyte mobilization, limited myocardial injury and improved heart function after acute MI in mice. Results in various animal models; Availability and safety of humanized monoclonal anti-CD20 antibodies in humans. (Zouggari Y. et al., Nat Med. 2013 Oct;19(10):1273-80; Ait-Oufella H. et al., J Exp Med. 2010 Aug 2;207(8):1579-87.)

Keywords: Atherosclerosis, B cell depleting agent, B cell, Anti-CD20 mAb, CD20, Antibody
Patent Application number: European Procedure (Patents) (EPA) - 06 Janv. 2009 - 09 290 005.9
Inventors:
TEDGUI AlainTEDDER ThomasAIT-OUFELLA Hafid
Publications:
Zouggari Y. et al. Nat Med. 2013 Oct;19(10):1273-80; Ait-Oufella H. et al. J Exp Med. 2010 Aug 2;207(8):1579-87.

Reference:

BIO08404-T1

    Business Developper
    contact
    Aymeric Empereur
    Business Developer
    Patent filling date: 07-01-2009
    Rare disease: No
    Second indication: Yes

    You might also be interested in